ArticleInfectious diseases and therapy2026
Real-World Therapy with Eravacycline for Complex Infections Caused by Carbapenem-Resistant Pathogens with a Focus on Patients with Severe Burns.
Article in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe purpose of this study was to describe the clinical outcomes in patients with complex infections caused by carbapenem-resistant pathogens who were treated with eravacycline (ERV) containing regimens.
methodsA retrospective chart review was conducted at Hospital St. Georg in Leipzig, Germany, a municipal tertiary care center with specialized departments for infectious diseases and tropical medicine, septic surgery, and severe burn injuries, between 1 January 2023 and 31 December 2025.
resultsEight patients (median age 38 years, 75% male) with bloodstream infections, hospital-acquired pneumonia, complex skin and soft tissue infections, and osteomyelitis were identified. Underlying conditions included severe burns, multiple myeloma, and human immunodeficiency virus (HIV) infection. The causative pathogens were carbapenemase-producing Klebsiella pneumoniae (KPC-2, NDM-1, and OXA-48) and carbapenemase-producing Acinetobacter baumannii (OXA-23, OXA-40, OXA-58, and OXA-72), including strains that expressed multiple carbapenemases. The minimum inhibitory concentrations (MICs) for ERV ranged from < 0.12 to 1.0 µg/mL. Five patients received monotherapy with ERV (100 mg twice per day (BID) intravenous (IV)), and three patients received combination therapy at the same dose along with other antimicrobial agents (ceftazidime/avibactam, sulbactam, and gentamicin). The median duration of treatment with ERV was 10 days (range 5-42 days). Clinical cure was achieved in 87.5% of patients (7/8), and all patients-with the exception of one patient with major skin and soft tissue defects and osteomyelitis-showed evidence of microbiological pathogen eradication, apart from extensive burn wounds. ERV at an increased standard dose of 100 mg BID IV was well tolerated, and no adverse events leading to treatment discontinuation were reported.
conclusionsIn this small retrospective study presenting preliminary real-world observational data, ERV proved to be a safe and promising treatment option for complex infections caused by carbapenemase-producing Klebsiella pneumoniae and Acinetobacter baumannii strains, characterized by few side effects and good efficacy even outside indications specified in the approval studies.
Indexed as
Identifiers
42663929What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.